Skip to main content

Celgene Corp. (CELG) - Get Celgene Corporation Report has settled a lawsuit for $280 million that was brought by a whistle blower claiming the company promoted off-label uses for two of its cancer drugs.

The lawsuit accused the company of promoting Revlimid and Thalomid for uses not prescribed on the drugs' labels, in turn defrauding federal and state Medicare programs out of billions of dollars as doctors prescribed the drugs for uses that were not specified on its label. 

The lawsuit was brought by Beverly Brown, a former sales representative for the company. 

Scroll to Continue

TheStreet Recommends

Watch More with TheStreet: